Ascendis Pharma A/S - Announces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia

Ascendis Pharma A/S NASDAQ:ASND:

• ASCENDIS PHARMA A/S - ANNOUNCES WEEK 104 DATA FROM APPROACH TRIAL OF TRANSCON CNP IN CHILDREN WITH ACHONDROPLASIA

• ASCENDIS PHARMA A/S - TRANSCON CNP SHOWS CONTINUED IMPROVEMENTS IN LOWER EXTREMITY ALIGNMENT THROUGH TWO YEARS OF TREATMENT